Đánh giá đáp ứng hóa trị bước 2 phác đồ folfiri – bevacizumab trên bệnh nhân ung thư đại trực tràng di căn tại Bệnh viện Ung Bướu Đà Nẵng=Evaluation of second-line chemotherapy response to the folfiri-bevacizumab regimen in metastatic colorectal cancer at the Da Nang Oncology Hospital

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Phương Thảo Nguyên Hồ, Thị Bích Ngọc Lê, Xuân Quang Nguyễn

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2024

Mô tả vật lý: tr.170-175

Bộ sưu tập: Metadata

ID: 245938

Thêm vào giỏ

Đánh giá đáp ứng và tác dụng phụ của hoá trị bước 2 phác đồ FOLFIRI – BEVACIZUMAB trên bệnh nhân ung thư đại trực tràng di căn Phương pháp: Nghiên cứu hồi cứu, mô tả loạt ca 30 bệnh nhân ung thư đại trực tràng di căn được điều trị hóa trị bước 2 phác đồ FOLFIRI – BEVACIZUMAB Kết quả: 30 bệnh nhân ung thư đại trực tràng di căn không còn khả năng phẫu thuật triệt căn được đưa vào nghiên cứu. Sau 4 chu kỳ, tỷ lệ kiểm soát bệnh là 83,3%. Không có bệnh nhân đáp ứng hoàn toàn, tỷ lệ đáp ứng một phần là 20%, bệnh ổn định là 63,3%, bệnh tiến triển 16,7%.Có 1 trường hợp bị dò, thủng ống tiêu hóa độ 3 phải ngưng điều trị và can thiệp bằng phẫu thuật. Hầu hết các bệnh nhân còn lại dung nạp hóa trị tốt với độc tính chủ yếu ở độ 1- 2 và có thể kiểm soát được. Kết luận: Phác đồ Bevacizumab kết hợp FOLFIRI là một phác đồ có hiệu quả tốt, cho tỷ lệ đáp ứng, tỷ lệ kiểm soát bệnh cao và các tác dụng không mong muốn ở mức có thể kiểm soát được.Evaluate the response and side effects of second-line chemotherapy FOLFIRI - BEVACIZUMAB regimen in patients with metastatic colorectal cancer. Methods: Retrospective study, describing a series of cases of 30 patients with mCRC treated with second-line chemotherapy FOLFIRI – BEVACIZUMAB regimen. Result: 30 patients with mCRC who were no longer candidates for radical surgery were included in the study. After 4 cycles, no patients responded copletely , partial rate was 20%, stable disease was 63,3%, progression was 16,75% . There was 1 case of grade 3 gastrointestinal fistula and perforation that required treatment discontinuation and surgical intervention. Most of the remaining patients tolerated chemotherapy well with mainly grade 1-2 toxicities that were controllable. Conclusion: Adding Bevacizumab to FOLFIRI chemothethary is good effective regimen, significantly improved response rate, disease control rate and controllable side effects.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR